Cargando…
Aspects of inflammatory bowel disease during the COVID-19 pandemic and general considerations()
So far, available evidence suggests that patients with inflammatory bowel disease (IBD) are not at greater risk for developing COVID-19 infection. In regard to patients with IBD remission: 5-aminosalycylates (5-ASAs) do not increase the risk for infection and should be continued. There is no need to...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321053/ http://dx.doi.org/10.1016/j.rgmxen.2020.05.001 |